GATC Health Corp announces completion of world’s first Viral Immunity platform

GATC Health Corp, developer of Predictive Multiomics™, announces the completion of its Viral Immunity platform. This platform analyzes an individual’s whole genome to determine immune response, infection tolerance and possible health complications from viral infection. This platform is customized to evaluate health risks for the most virulent and dangerous viruses at any point in time.

The Viral Immunity platform is a digital neural network operating in conjunction with the company’s powerful Multiomics Advanced Technology™ or MAT. MAT analyzes genomic data as well as other biological datasets (multiomics) to allow accurate predictions regarding outcomes to specific health risks. GATC believes this is the first platform of its kind to determine an individual’s risk of exposure to viruses such as H1N1, Ebola and SARS-CV-2.

Currently, the platform is in the early stages of beta testing. It is expected that the company will announce a licensing agreement for the Viral Immunology platform in the near future.

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities.  This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information.  The Company reserves the right to modify or amend the information contained herein.